M. GUMUS Et Al. , "EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.," 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , vol.35, Illinois, United States Of America, 2017
GUMUS, M. Et Al. 2017. EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.. 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , (Illinois, United States Of America).
GUMUS, M., GEREDELI, C., UCAR, M., KAYA, S., DEMIR, H., UNAL, O. U., ... DEGIRMENCI, M.(2017). EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab. . 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America
GUMUS, Mahmut Et Al. "EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.," 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2017
GUMUS, Mahmut Et Al. "EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.." 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , Illinois, United States Of America, 2017
GUMUS, M. Et Al. (2017) . "EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.." 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Mahmut GUMUS Et Al. }, title={EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.}, congress name={53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET}, city={Illinois}, country={United States Of America}, year={2017}}